Melanoma.
Copyright policy )Melanoma.
Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec- tively. The management of immune related toxicities is keypoint for adequate use of these agents.
- Shinshu University Japan
Mitogen-Activated Protein Kinase Kinases, Proto-Oncogene Proteins B-raf, Clinical Trials as Topic, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Humans, Antineoplastic Agents, Immunotherapy, Protein Kinase Inhibitors, Ipilimumab, Melanoma
Mitogen-Activated Protein Kinase Kinases, Proto-Oncogene Proteins B-raf, Clinical Trials as Topic, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Humans, Antineoplastic Agents, Immunotherapy, Protein Kinase Inhibitors, Ipilimumab, Melanoma
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!